Remove Chemotherapy Remove Diabetes Remove Drug Development
article thumbnail

Camrelizumab by Jiangsu Hengrui Medicine for Solid Tumor: Likelihood of Approval

Pharmaceutical Technology

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

article thumbnail

Advancing microbiome innovation

European Pharmaceutical Review

For example, numerous publications have highlighted the role of the gut microbiome in improving the efficacy and diminishing the toxicity of chemotherapeutic drugs. Emerging Evidence Of The Gut Microbiome In Chemotherapy: A Clinical Review. References US FDA approves Ferring’s Rebyota for Clostridioides difficile infection.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies

Pharmacy Times

SHOW MORE With robust pipelines, cell therapy remains the major driver for drug development. 4 Nononcology applications are growing, however, particularly for conditions such as osteoarthritis, type 1 diabetes, and Parkinson disease. The most targeted cancers include acute myeloid leukemia, liver cancer, and pancreatic cancer.

article thumbnail

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

CMS is issuing unique J-codes for 505(b)(2) drugs, classifying them as sole-source products if not therapeutically equivalent. This pathway reduces submission denial risk, accelerates drug development, and offers potential market exclusivity for up to 7 years.

article thumbnail

Combating antimicrobial resistance with a viable alternative to traditional antibiotics

pharmaphorum

In order to reduce the global healthcare impact of the evolving AMR situation, companies such as Micreos Pharmaceuticals are taking a novel and highly innovative approach to antibacterial drug development by developing targeted antimicrobial products. Antimicrobial Agents and Chemotherapy 2022. References. Herpers, P.

article thumbnail

Pembrolizumab by Merck for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Pharmaceutical Technology

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.